4.7 Review

Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside

期刊

CLINICAL MICROBIOLOGY AND INFECTION
卷 20, 期 -, 页码 54-59

出版社

WILEY-BLACKWELL
DOI: 10.1111/1469-0691.12495

关键词

Aspergillus; Candida; mutations; mycosis; tandem repeat

资金

  1. Astellas Pharma
  2. bioMerieux
  3. Gilead Sciences
  4. Merck Sharp and Dohme
  5. Pfizer
  6. Schering Plough
  7. Soria Melguizo SA
  8. Ferrer International
  9. European Union
  10. ALBAN programme
  11. Spanish Agency for International Cooperation
  12. Spanish Ministry of Culture and Education
  13. Spanish Health Research Fund
  14. Instituto de Salud Carlos III
  15. Ramon Areces Foundation
  16. Mutua Madrilena Foundation

向作者/读者索取更多资源

The phenotypic methods for identification of antifungal resistance are reliable procedures, and MIC determination by reference techniques is the gold standard to detect resistant clinical isolates. In recent years, progress has been made towards the description of resistance mechanisms at molecular level. There are methods of detection that can be useful for clinical laboratories, but lack of standardization precludes their full and effective integration in the routine daily practice. The molecular detection of Candida resistance to azoles and to echinocandins and of Aspergillus resistance to triazoles can be clinically relevant and could help to design more efficient prevention and control strategies. This text reviews the present state of the detection of mechanisms of resistance at the molecular level in Candida spp. and Aspergillus spp. and its relevance to clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据